ArticleClinical drug investigation2021

Cerebrospinal Fluid and Clinical Profiles in Adult Type 2-3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience.

Giammarco Milella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.